Effects of oral hormone replacement therapy on mean platelet volume in postmenopausal women

Kaygusuz, İkbal; Simavlı, Serap; Eser, Ayla; Gümüş, İlknur İnegöl; Yüksel, Selcen; Duvan, Zehra Candan Iltemir; Kafalı, Hasan

doi:10.3906/sag-1311-88

Cited by 3 publications

(4 citation statements)

References 17 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…before exercise, which was manifested in increased, compared to the OC(-) group, platelet aggregation in the ADP assay. According to some researchers, increased platelet reactivity in women taking oral contraceptives may be caused by an increase in the percentage of large platelets, resulting from accelerated turnover of platelets [23,24,25]. In the presented study, increased turnover of platelets in women taking OC is shown by, firstly, the increased platelet distribution width (PDW) and a slightly lower number of platelets [in comparison with the OC(-) group], and secondly, by a strong positive correlation between the PDW and platelet volume (MPV) and a negative correlation between MPV and the PLT count.…”

Section: Discussionmentioning

confidence: 99%

“…Among other potential mechanisms of the thrombotic action of hormonal contraceptives, the intensity of the myeloid trombocytopoesis and increased platelet reactivity should be considered. The increase in platelet reactivity under the influence of estradiol is perhaps a consequence of an increase in the percentage of large platelets, which is also reflected in an increase in platelet volume (MPV) [23,24,25].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early response of selected haemostatic and haematological parameters to physical activity in young women – the potential impact of oral contraceptives

Jastrzębska¹,

Żyżniewska-Banaszak²,

Nawrot³

et al. 2017

J Pre Clin Clin Res.

View full text Add to dashboard Cite

Early response of selected haemostatic and haematological parameters to physical activity in young women -the potential impact of oral contraceptives. J Pre Clin-Clin Res. 2017; 11(1): 15-21. doi: 10.26444/jpccr/75148 Abstract Introduction and objective. Exercise (submaximal) in untrained subjects can modify haemostasis toward hypercoagulability, especially among women using oral contraceptives (OC). The aim of this study was to investigate whether this can be explained by platelet haemostasis and changes in the generation of membrane microparticles. Materials and method. Young, healthy women (n=60) were divided into 2 equal groups: a study group OC (+) who had used OC for >3 months, and controls who had never used oral contraceptives OC(-). Exclusion criteria: those with systematic daily physical activity. Participants were subjected to treadmill exercise (Cardiac Diagnostic System; model CH2000) using the Bruce protocol/ AHA guidelines. Platelet aggregation with arachidonic acid (ASPI test) or ADP (ADP test), membrane microparticle (MP) activity, plasma coagulation times (APTT/PT) and blood count were determined before and 45 minutes after exercise. Results. Before exercise, the OC(+) group had slightly higher platelet aggregation (ADP test), significantly lower MP activity, slightly lower PLT and slightly higher PDW rate. Exercise caused slight inhibition of platelet aggregation (ASPI test), and significant decrease in MP activity -only in the OC(-) group. After exercise, in both groups there was a significant decrease in PLT and increase in WBC, more pronounced in OC(+) group. Conclusions. Submaximal exercise was beneficial for haemostasis in women not using hormonal contraception, associated primarily with reduced MP activity. No beneficial effects of physical activity were found for women using hormonal contraceptives, possibly associated with a hypercoagulable state, and higher reactivity of blood platelets under the influence of the use of contraceptives.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Early response of selected haemostatic and haematological parameters to physical activity in young women – the potential impact of oral contraceptives

Jastrzębska¹,

Żyżniewska-Banaszak²,

Nawrot³

et al. 2017

J Pre Clin Clin Res.

View full text Add to dashboard Cite

show abstract

“…Известно, что PAI-1 является маркером субклинического воспаления и, наряду с С-реактивным белком и IL-6, ассоциируется с инсулинорезистентностью и гипертензией [16]. Приведенные данные, наряду с результатами аналогичных исследований [17,18], могут свидетельствовать в пользу снижения риска сердечно-сосудистых заболеваний у женщин с МС в постменопаузе на фоне приема 17β-эстрадиол/дроспиренон.…”

Section: таблица эффективность терапии климактерического синдрома коunclassified

Effectiveness and safety of 17β-estradiol / drospirenon для менопаузальной гормональной терапии у пациенток с риском развития метаболического синдрома

Селедцова¹,

Ovsyannikova²

2016

Med. sov.

View full text Add to dashboard Cite

В настоящее время перед медицинским сообществом остро стоит проблема сохранения активности и работоспособности женщин в постменопаузе. Актуальность данной темы обусловлена увеличением продолжительности жизни женщин и изменением их социального статуса. По данным Росстата за 2014 г., средняя продолжительность жизни женщин в России-77,2 года. С наступлением менопаузы отмечается снижение выработки эстрогенов, что может сопровождаться психоэмоциональными, вегетососудистыми нарушениями, увеличением риска сердечно-сосудистых заболеваний, развитием метаболического синдрома (МС), увеличением частоты остеопороза [1, 2]. Патогенетической терапией менопаузальных симптомов является индивидуально подобранная заместительная гормональная терапия. Поскольку у большинства женщин в постменопаузе имеет место та или иная экстрагенитальная патология, среди которой лидирует МС с инсулинорезистентностью, нарушением липидного обмена, наличием артериальной гипертензии, особый интерес представляет комбинация 17β-эстрадиол/дроспиренон. Данный препарат содержит эстроген эстрадиол, который идентичен естественному 17β-эстрадиолу, и производное спиронолактона дроспиренон, обладающий гестагенным, антигонадотропным, антиандрогенным и антиминералокортикоидным действием. В докли-Н.В. СЕЛЕДЦОВА, к.м.н., Т.В. ОВСЯННИКОВА, д.м.н. Институт химической биологии и фундаментальной медицины Сибирского отделения РАН, ООО «Центр персонализированной медицины», Новосибирск ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ПРИМЕНЕНИЯ КОМБИНАЦИИ 17β-ЭСТРАДИОЛ/ДРОСПИРЕНОН ДЛЯ МЕНОПАУЗАЛЬНОЙ ГОРМОНАЛЬНОЙ ТЕРАПИИ У ПАЦИЕНТОК С РИСКОМ РАЗВИТИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА Цель работы: исследование эффективности и безопасности назначения комбинации 17β-эстрадиол/дроспиренон у пациенток с различными проявлениями климактерического синдрома и риском развития метаболического синдрома. Материалы и методы. Проанализированы результаты двухлетнего лечения климактерического синдрома препаратом 17β-эстрадиол/дроспиренон у 21 пациентки в постменопаузе. Результаты. В результате двухлетнего приема препарата 17β-эстрадиол/дроспиренон у пациенток с риском развития метаболического синдрома отмечалось достоверное снижение индекса Куппермана, а также улучшение состояния кожи и слизистых оболочек. Не было выявлено отрицательного влияния препарата на показатели липидного обмена и параметры гемостаза, уровень артериального давления, рост миоматозных узлов и толщины эндометрия. Выводы. Комбинация 17β-эстрадиол/дроспиренон является эффективной и безопасной в терапии климактерических нарушений и может являться препаратом выбора у пациенток с риском развития метаболического синдрома.

show abstract

“…Studies have indicated that estrogen can regulate lipid homeostasis in the adipose tissue, liver and brain, as well as prevent metabolic dyslipidemia [13]. Furthermore, clinical evidence demonstrates that estrogen replacement therapy can reduce the risk of cardiovascular disease in postmenopausal women by improving lipid metabolism [14, 15]. Further studies are needed to identify the mechanisms by which estrogen regulates lipid metabolism and delays the development of cardiovascular disease in postmenopausal women.…”

Section: Introductionmentioning

confidence: 99%

Estrogen stimulates SREBP2 expression in hepatic cell lines via an estrogen response element in the SREBP2 promoter

Meng

Zong

2019

Cell Mol Biol Lett

View full text Add to dashboard Cite

ObjectiveHypoestrogenism in women is strongly associated with menopause and it can lead to lipid disorder, which predisposes people to premature cardiovascular disease. However, the mechanism of lipid disorder remains unclear. Sterol regulatory element-binding protein 2 (SREBP2) is the key transcription factor regulating cholesterol metabolism. We hypothesize that estrogen regulates SREBP2 transcription through an estrogen response element (ERE) in the SREBP2 promoter region.MethodsHuman hepatoblastoma cells (HepG2) were treated with dose-dependent concentrations of estradiol (E2) for 24 h. Then, SREBP2 expression was determined via real-time PCR and immunofluorescence. The expressions of the SREBP2 downstream target genes HMGCR and LDLR were determined via real-time PCR. Lipid secretion in the culture media of HepG2 cells was measured using ELISA. Through bioinformatics analysis, we identified high-scoring ERE-like sequences in the SREBP2 gene promoter. Chromatin immunoprecipitation analysis was used to confirm the ERE. DNA fragments of the putative or mutated ERE-like sequence were synthesized and ligated into pGL3-basic plasmid to construct the SREBP2 promoter luciferase reporter systems. SREBP2-Luciferase (SREBP2-Luc), SREBP2-Mutation (SREBP2-Mut) and the blank control were transfected into hepatic cell lines. Luciferase activities were measured using the dual-luciferase reporter assay system. Chromatin immunoprecipitation analysis and the luciferase reporter assay were repeated in human hepatoma cells (HuH-7).ResultsWe found that E2 dose-dependently increased the expression of SREBP2 in HepG2 cells and that the increased levels were blocked when treated with an estrogen receptor-alpha antagonist. Additionally, E2 increased both HMGCR and LDLR expression and lipid secretion in HepG2 cells. Notably, we identified a functional ERE in the SREBP2 gene promoter, to which E2 could specifically bind and induce transcription.ConclusionsAn ERE was identified in the SREBP2 gene promoter. It mediates the regulation of SREBP2 expression by estrogen in hepatocytes. This study provides a mechanism to link cardiovascular disease with estrogen.

show abstract

Effects of oral hormone replacement therapy on mean platelet volume in postmenopausal women

Cited by 3 publications

References 17 publications

Early response of selected haemostatic and haematological parameters to physical activity in young women – the potential impact of oral contraceptives

Early response of selected haemostatic and haematological parameters to physical activity in young women – the potential impact of oral contraceptives

Effectiveness and safety of 17β-estradiol / drospirenon для менопаузальной гормональной терапии у пациенток с риском развития метаболического синдрома

Estrogen stimulates SREBP2 expression in hepatic cell lines via an estrogen response element in the SREBP2 promoter

Contact Info

Product

Resources

About